PRTK Paratek Pharmaceuticals, Inc.

21.60
+0  (1%)
Previous Close 21.35
Open 21.40
Price To book 6.97
Market Cap 524.58M
Shares 24,286,000
Volume 480,462
Short Ratio 2.00
Av. Daily Volume 621,824

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved November 23, 2011.
Intermezzo
Insomnia
Phase 3 data due 2Q 2017.
Omadacycline - oral
Acute bacterial skin and skin structure infections (ABSSSI)
Phase 3 topline data met endpoints - June 2016
Omadacycline
Acute bacterial skin and skin structure infections (ABSSSI)
Phase 3 data released April 3, 2017 - all endpoints met.
Omadacycline
Community-acquired bacterial pneumonia (CABP)
Phase 3 data released March 27 2017 - primary endpoints met. NDA filing due 2H 2017.
Sarecycline
Severe acne vulgaris

Latest News

  1. Why Paratek Pharmaceuticals (PRTK) Could Be Positioned for a Surge?
  2. Paratek Pharmaceuticals to Present New Data from Omadacycline Development Program at ECCMID 2017
  3. Paratek (PRTK) Stock Continues to Rise on Positive Results
  4. Today's Research Reports on Biotech Stocks to Watch: Benitec Biopharma and Paratek Pharmaceuticals
  5. Rising Biotechs: Paratek Among Stocks Surging On Trial Results
  6. Why Southwestern Energy, Paratek Pharmaceuticals, and AmTrust Financial Services Jumped Today
  7. Paratek Pharma's Pneumonia Antibiotic Succeeds
  8. Paratek shares soar as antibiotic passes late-stage hurdle
  9. Why Paratek Pharmaceuticals Inc Is Soaring
  10. Is This the Turnaround Paratek Has Been Looking For?
  11. Biotech Movers: Paratek Spikes 34%
  12. Why Paratek Pharmaceuticals Inc (PRTK) is Surging
  13. After-hours buzz: PRTK, MRCY, NVCR
  14. Paratek Pharma shares surge 30% after antibiotic study results
  15. Paratek's antibiotic succeeds in second late-stage study
  16. Paratek Announces Positive Phase 3 Study of Omadacycline in Community-Acquired Bacterial Pneumonia
  17. Did This Beauty Giant Just Solve The Acne Challenge?
  18. Allergan Acne Candidate Meets Endpoints in Phase III Studies
  19. Blog Coverage Allergan and Paratek's Acne Drug Reported Positive Results
  20. Allergan, Paratek’s Acne Drug Succeeds in Phase 3

SEC Filings

  1. D - Notice of Exempt Offering of Securities 14900882
  2. 15-12G - Securities registration termination (Section 12(g)) 131065901
  3. 8-K - Current report 111170754
  4. NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 111112169
  5. 8-K - Current report 111110230
  6. 8-K - Current report 11986107
  7. 8-K - Current report 11851975
  8. 8-K - Current report 11825838
  9. 10-Q - Quarterly report (Sections 13 or 15(d)) 11822565
  10. 8-K - Current report 11720538